{
  "drug_name": "Terazosin",
  "url": "https://wikem.org/wiki/Terazosin",
  "scraped_at": "2026-01-10T08:03:18.501203",
  "sections": {
    "Administration": {
      "text": "Type: α-blocker\nDosage Forms: CAP: 1 mg, 2 mg, 5 mg, 10 mg\nRoutes of Administration: Oral\nCommon Trade Names: Hytrin",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Benign_prostatic_hyperplasia": {
          "text": "1-10 mg PO qhs",
          "tables": []
        },
        "Hypertension": {
          "text": "1-10 mg PO qhs",
          "tables": []
        },
        "Urolithiasis": {
          "text": "Off-label: 2-5 mg PO qhs",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Benign_prostatic_hyperplasia": {
      "text": "1-10 mg PO qhs",
      "subsections": {
        "Hypertension": {
          "text": "1-10 mg PO qhs",
          "tables": []
        },
        "Urolithiasis": {
          "text": "Off-label: 2-5 mg PO qhs",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hypertension": {
      "text": "1-10 mg PO qhs",
      "subsections": {
        "Urolithiasis": {
          "text": "Off-label: 2-5 mg PO qhs",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Urolithiasis": {
      "text": "Off-label: 2-5 mg PO qhs",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "Safety/efficacy not established",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: C. weigh risk/benefit during pregnancy; no human data available\nLactation risk\n: Infant risk cannot be ruled out; weigh risk/benefit while breastfeeding",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult: No adjustment",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult: No adjustment",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Renal_Dosing": {
      "text": "Adult: No adjustment",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "Adult: No adjustment",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "Adult: No adjustment",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to drug/class",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Hypotension\nSyncope\nPriapism",
          "tables": []
        },
        "Common": {
          "text": "Orthostatic hypotension\nDizziness\nHeadache\nWeakness\nNausea\nNasal Congestion",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Priapism",
          "url": "https://wikem.org/wiki/Priapism"
        }
      ]
    },
    "Serious": {
      "text": "Hypotension\nSyncope\nPriapism",
      "subsections": {
        "Common": {
          "text": "Orthostatic hypotension\nDizziness\nHeadache\nWeakness\nNausea\nNasal Congestion",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Priapism",
          "url": "https://wikem.org/wiki/Priapism"
        }
      ]
    },
    "Common": {
      "text": "Orthostatic hypotension\nDizziness\nHeadache\nWeakness\nNausea\nNasal Congestion",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 12-14 hrs\nMetabolism: CYP450\nExcretion: Feces (60%) and renal (40%)",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "α-1A antagonist → smooth muscle relaxation in bladder neck, prostate, urethra → increased urine flow rate (See\nTamsulosin\n)\nTheoretically less specific for bladder a-1 receptors and thus has a higher risk for orthostatic hypotension\nIn a single-center European RCT, terazosin (vs tamsulosin) appears to be associated with a higher rate of symptomatic orthostatic hypotension\n[1]\nIn a meta-analysis from a Chinese team, more subjects receiving terazosin (vs tamsulosin) experienced dizziness and hypotension\n[2]",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Tamsulosin",
          "url": "https://wikem.org/wiki/Tamsulosin"
        }
      ]
    },
    "See_Also": {
      "text": "Alpha blockers\nTamsulosin",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Alpha blockers",
          "url": "https://wikem.org/wiki/Alpha_blockers"
        },
        {
          "text": "Tamsulosin",
          "url": "https://wikem.org/wiki/Tamsulosin"
        }
      ]
    }
  }
}